Madrigal Pharmaceuticals Reports 2018 Fourth Quarter and Full Year Financial Results and Highlights
27 févr. 2019 06h50 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its fourth quarter and full year 2018 financial results and highlights: “Madrigal...
Phase 2 Results for Madrigal’s MGL-3196 in Non-Alcoholic Steatohepatitis (NASH) Presented during Presidential Plenary Clinical Session of The Liver Meeting® 2018
12 nov. 2018 11h30 HE
|
Madrigal Pharmaceuticals, Inc.
-- Statistically significantly more NASH resolution in MGL-3196 as compared with placebo in a Phase 2 clinical trial support MGL-3196 as a first- and potentially best-in class thyroid hormone receptor...
ACC, AHA Release 2018 Guideline on the Management of Blood Cholesterol at AHA Scientific Sessions
10 nov. 2018 12h55 HE
|
National Lipid Association
NLA among 12 organizations to co-author, endorse key document for reducing risk of atherosclerotic cardiovascular disease CHICAGO, Nov. 10, 2018 (GLOBE NEWSWIRE) -- The American College of...
Madrigal Pharmaceuticals Reports 2018 Third Quarter Financial Results and Highlights Upcoming Clinical Events
06 nov. 2018 06h50 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its third quarter 2018 financial results and described upcoming clinical events: ...
Madrigal Pharmaceuticals Reports 2018 Second Quarter Financial Results and Reviews Key Clinical Achievements
07 août 2018 06h50 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its second quarter 2018 financial results and described recent clinical and...
Madrigal Pharmaceuticals Prices Public Offering of Common Stock
06 juin 2018 23h14 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., June 06, 2018 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq:MDGL), a clinical-stage biopharmaceutical company focused on the development and commercialization of...
Madrigal Pharmaceuticals Announces Proposed Public Offering of Common Stock
05 juin 2018 16h10 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., June 05, 2018 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq:MDGL), a clinical-stage biopharmaceutical company focused on the development and commercialization of...
Madrigal’s MGL-3196 Achieves Liver Biopsy Endpoints in Patients with Non-alcoholic Steatohepatitis (NASH) at 36 Weeks in Phase 2 Clinical Trial
31 mai 2018 06h50 HE
|
Madrigal Pharmaceuticals, Inc.
-- Statistically significantly more patients treated with MGL-3196 compared with placebo treated patients achieved a two point reduction in NAS (NAFLD activity score) on biopsy -- -- Statistically...
Madrigal Pharmaceuticals Reports 2018 First Quarter Financial Results and Reviews Key Clinical Achievements
08 mai 2018 06h50 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., May 08, 2018 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its first quarter 2018 financial results. During the first quarter, the Company...
Leading Cardiologist Dr. Neil Stone Secured as Speaker for the National Lipid Association Conference
18 juil. 2016 12h47 HE
|
National Lipid Association
JACKSONVILLE, FL--(Marketwired - July 18, 2016) - Award-winning cardiologist, Neil J. Stone, MD, FACC, FNLA, will be the keynote speaker at the National Lipid Association (NLA) Clinical Lipid Update...